Science Supporting Ephedra Ban Fails FDA’s Own Standard – Nutraceutical
This article was originally published in The Tan Sheet
Executive Summary
Scientific evidence used by FDA to support its outright ban of ephedra would not meet the agency's "own criteria for competent scientific evidence," low-dose ephedra marketer Nutraceutical asserts
You may also be interested in...
GMP Cost Impact, Ephedra Suits Loom Over Supplement Industry – Israelsen
The Office of Management & Budget likely is delayed in releasing GMPs because it is grappling with issues surrounding the economic impact of the rule on small businesses, according to UNPA head Loren Israelsen
GMP Cost Impact, Ephedra Suits Loom Over Supplement Industry – Israelsen
The Office of Management & Budget likely is delayed in releasing GMPs because it is grappling with issues surrounding the economic impact of the rule on small businesses, according to UNPA head Loren Israelsen
GMP Cost Impact, Ephedra Suits Loom Over Supplement Industry – Israelsen
The Office of Management & Budget likely is delayed in releasing GMPs because it is grappling with issues surrounding the economic impact of the rule on small businesses, according to UNPA head Loren Israelsen